Samantha Cote
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samantha Cote has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Whittingstall
Université de Sherbrooke
3 shared publications Adrianna Mendrek
Faculty of Arts and Sciences, Department of Psychology Bishop's University Sherbrooke Quebec Canada
1 shared publication- Alexia Coulombe-Leveque
École de réadaptation, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, Canada
1 shared publication Artuela Çaku
Sherbrooke University Hospital Research Center Sherbrooke Canada
1 shared publicationCamille Champigny
Sherbrooke University Hospital Research Center Sherbrooke Canada
1 shared publication- Christian Bocti
Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC, Canada; Research Centre on Aging, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada
1 shared publication
Latest Publications
- Open Access
Higher Brain Grey Matter Density in Mild to Moderate Chronic Low Back Pain Patients
Chronic low back pain (CLBP) is the leading cause of disability worldwide. Structural abnormalities in the lumbar region rarely account for the pain symptoms observed. In contrast, the brain plays a central role in chronic pain, with several studies suggesting that chronic pain may result from the persistence of pain memories and/or the inability to extinguish these memories following an initial inciting injury. Previous research has reported a reduction in grey matter density (GMD) in CLBP patients, as measured by magnetic resonance imaging (MRI). Notably, lower GMD has been observed in patients with moderate to severe CLBP who are undergoing prescribed pharmacological treatments. However, it remains unclear whether these differences in GMD could be associated with a less severe condition. This study aimed to investigate whether GMD is altered in a cohort with mild to moderate CLBP symptoms, and who have not been prescribed pharmacological treatments. To achieve this, we acquired T1-weighted MRI scans from 25 healthy controls (HC) and 27 untreated individuals with mild to moderate CLBP. Scans were taken at baseline, 2 months, and 4 months after baseline. GMD analysis was carried out using the FMRIB Software. Our results consistently showed higher GMD in the CLBP group compared to HC. These findings suggest that the observed alterations in GMD may be related to the condition itself, and can occur even in patients with milder symptoms and better physical function, without the influence of opioids, anticonvulsants, or antidepressants. Given that our participants differ from those typically studied in the literature, our results imply that they may be in a distinct brain state relative to the condition. Further research is needed to elucidate the underlying biological mechanisms and confirm whether these brain alterations are indeed a characteristic feature of CLBP.
Open AccessHigher Brain Grey Matter Density in Mild to Moderate Chronic Low Back Pain Patients
Chronic low back pain (CLBP) is the leading cause of disability worldwide. Structural abnormalities in the lumbar region rarely account for the pain symptoms observed. In contrast, the brain plays a central role in chronic pain, with several studies suggesting that chronic pain may result from the persistence of pain memories and/or the inability to extinguish these memories following an initial inciting injury. Previous research has reported a reduction in grey matter density (GMD) in CLBP patients, as measured by magnetic resonance imaging (MRI). Notably, lower GMD has been observed in patients with moderate to severe CLBP who are undergoing prescribed pharmacological treatments. However, it remains unclear whether these differences in GMD could be associated with a less severe condition. This study aimed to investigate whether GMD is altered in a cohort with mild to moderate CLBP symptoms, and who have not been prescribed pharmacological treatments. To achieve this, we acquired T1-weighted MRI scans from 25 healthy controls (HC) and 27 untreated individuals with mild to moderate CLBP. Scans were taken at baseline, 2 months, and 4 months after baseline. GMD analysis was carried out using the FMRIB Software. Our results consistently showed higher GMD in the CLBP group compared to HC. These findings suggest that the observed alterations in GMD may be related to the condition itself, and can occur even in patients with milder symptoms and better physical function, without the influence of opioids, anticonvulsants, or antidepressants. Given that our participants differ from those typically studied in the literature, our results imply that they may be in a distinct brain state relative to the condition. Further research is needed to elucidate the underlying biological mechanisms and confirm whether these brain alterations are indeed a characteristic feature of CLBP.
- Open Access
- 9 September 2024
- Published by Wiley in Autism Research
- Vol. 17 (9) , 1944-1956
Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial
Fragile X syndrome (FXS) is the primary hereditary cause of intellectual disability and autism spectrum disorder. It is characterized by exacerbated neuronal excitability, and its correction is considered an objective measure of treatment response in animal models, a marker albeit rarely used in clinical trials. Here, we used an extensive transcranial magnetic stimulation (TMS) battery to assess the neurophysiological effects of a therapy combining two disease‐modifying drugs, lovastatin (40 mg) and minocycline (100 mg), administered alone for 8 weeks and in combination for 12 weeks, in 19 patients (mean age of 23.58 ± 1.51) with FXS taking part in the LOVAmix trial. The TMS battery, which included the resting motor threshold, short‐interval intracortical inhibition, long‐interval intracortical inhibition, corticospinal silent period, and intracortical facilitation, was completed at baseline after 8 weeks of monotherapy (visit 2 of the clinical trial) and after 12 weeks of dual therapy (visit 4 of the clinical trial). Repeated measure ANOVAs were performed between baseline and visit 2 (monotherapy) and visit 3 (dual therapy) with interactions for which monotherapy the participants received when they began the clinical trial. Results showed that dual therapy was associated with reduced cortical excitability after 20 weeks. This was reflected by a significant increase in the resting‐motor threshold after dual therapy compared to baseline. There was a tendency for enhanced short‐intracortical inhibition, a marker of GABAa‐mediated inhibition after 8 weeks of monotherapy compared to baseline. Together, these results suggest that a combined therapy of minocycline and lovastatin might act on the core neurophysiopathology of FXS. This trial was registered at clinicaltrials.gov (NCT02680379).
- 9 September 2024
- Published by Wiley in Autism Research
- Vol. 17 (9) , 1944-1956
Open AccessNeurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial
Fragile X syndrome (FXS) is the primary hereditary cause of intellectual disability and autism spectrum disorder. It is characterized by exacerbated neuronal excitability, and its correction is considered an objective measure of treatment response in animal models, a marker albeit rarely used in clinical trials. Here, we used an extensive transcranial magnetic stimulation (TMS) battery to assess the neurophysiological effects of a therapy combining two disease‐modifying drugs, lovastatin (40 mg) and minocycline (100 mg), administered alone for 8 weeks and in combination for 12 weeks, in 19 patients (mean age of 23.58 ± 1.51) with FXS taking part in the LOVAmix trial. The TMS battery, which included the resting motor threshold, short‐interval intracortical inhibition, long‐interval intracortical inhibition, corticospinal silent period, and intracortical facilitation, was completed at baseline after 8 weeks of monotherapy (visit 2 of the clinical trial) and after 12 weeks of dual therapy (visit 4 of the clinical trial). Repeated measure ANOVAs were performed between baseline and visit 2 (monotherapy) and visit 3 (dual therapy) with interactions for which monotherapy the participants received when they began the clinical trial. Results showed that dual therapy was associated with reduced cortical excitability after 20 weeks. This was reflected by a significant increase in the resting‐motor threshold after dual therapy compared to baseline. There was a tendency for enhanced short‐intracortical inhibition, a marker of GABAa‐mediated inhibition after 8 weeks of monotherapy compared to baseline. Together, these results suggest that a combined therapy of minocycline and lovastatin might act on the core neurophysiopathology of FXS. This trial was registered at clinicaltrials.gov (NCT02680379).
- 14 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (20) , E1970-E1978
Association of Cumulative Lifetime Exposure to Female Hormones With Cerebral Small Vessel Disease in Postmenopausal Women in the UK Biobank
Background and Objectives: Rates of cerebrovascular disease increase after menopause which is often attributed to the absence of hormones. It remains unknown whether the cumulative exposure to hormones across a female person9s premenopausal life extends the window of cerebrovascular protection to the postmenopausal period. To investigate this, we examined the relationship between lifetime hormone exposure and cerebral small vessel disease in over 9 000 postmenopausal women in the UK-Biobank. Methods: The cohort consisted of women (aged 40 to 69) that attended one of 22 research centers across the United Kingdom between 2006-2010. Women were excluded if they were premenopausal when scanned, had missing reproductive history data, self-reported neurological disorders, brain cancer, cerebral vascular incidents, head or neurological injury and nervous system infection. Endogenous lifetime hormone exposure (LHEEndo) was estimated by summing the number of years pregnant (LHEparity) with the duration of the reproductive period (LHECycle = age menopause - age menarche). Exogenous lifetime hormone exposure (LHEExo) was estimated by summing the number of years on oralcontraceptives (LHEOC) and hormone replacement therapy (LHEHRT). Cerebral small vessel disease was determined by estimating white matter hyperintensity volume (WMHV) from T2-FLAIR brain MRI (acquired between 2014 and 2021), normalized to intracranial volume and log-transformed. Multiple linear regressions were used to assess the relationship between LHEEndo on WMHV adjusted for age, cardiovascular risk factors, sociodemographics and LHEExo. Results: A total of 9163 postmenopausal women (age = 64.21 {plus minus} 6.81) were retained for analysis. Average LHEEndo was 39.77 {plus minus} 3.59 years. Women with higher LHEEndo showed smaller WMHV (R2Adj = 0.307, LHEEndo β= -0.007 (-0.012, -0.002), p <0.01). LHEparity and LHECycle were independent contributors to WMHV (R2Adj =0.308, p<<0.001; LHEparity β=-0.022, (-0.042, -0.002), p <0.05; LHECycle β=-0.006, (-0.011, -0.001), p 0.05). Discussion: Women with more prolonged exposure to endogenous hormones show relatively smaller burden of cerebral small vessel disease independent of history of oralcontraceptive use or hormone replacement therapy. Our results highlight the critical role endogenous hormones play in female brain health and provide real-world evidence of the protective effects premenopausalendogenous hormone exposure plays on postmenopausalcerebrovascular health.
- 14 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (20) , E1970-E1978
Association of Cumulative Lifetime Exposure to Female Hormones With Cerebral Small Vessel Disease in Postmenopausal Women in the UK Biobank
Background and Objectives: Rates of cerebrovascular disease increase after menopause which is often attributed to the absence of hormones. It remains unknown whether the cumulative exposure to hormones across a female person9s premenopausal life extends the window of cerebrovascular protection to the postmenopausal period. To investigate this, we examined the relationship between lifetime hormone exposure and cerebral small vessel disease in over 9 000 postmenopausal women in the UK-Biobank. Methods: The cohort consisted of women (aged 40 to 69) that attended one of 22 research centers across the United Kingdom between 2006-2010. Women were excluded if they were premenopausal when scanned, had missing reproductive history data, self-reported neurological disorders, brain cancer, cerebral vascular incidents, head or neurological injury and nervous system infection. Endogenous lifetime hormone exposure (LHEEndo) was estimated by summing the number of years pregnant (LHEparity) with the duration of the reproductive period (LHECycle = age menopause - age menarche). Exogenous lifetime hormone exposure (LHEExo) was estimated by summing the number of years on oralcontraceptives (LHEOC) and hormone replacement therapy (LHEHRT). Cerebral small vessel disease was determined by estimating white matter hyperintensity volume (WMHV) from T2-FLAIR brain MRI (acquired between 2014 and 2021), normalized to intracranial volume and log-transformed. Multiple linear regressions were used to assess the relationship between LHEEndo on WMHV adjusted for age, cardiovascular risk factors, sociodemographics and LHEExo. Results: A total of 9163 postmenopausal women (age = 64.21 {plus minus} 6.81) were retained for analysis. Average LHEEndo was 39.77 {plus minus} 3.59 years. Women with higher LHEEndo showed smaller WMHV (R2Adj = 0.307, LHEEndo β= -0.007 (-0.012, -0.002), p <0.01). LHEparity and LHECycle were independent contributors to WMHV (R2Adj =0.308, p<<0.001; LHEparity β=-0.022, (-0.042, -0.002), p <0.05; LHECycle β=-0.006, (-0.011, -0.001), p 0.05). Discussion: Women with more prolonged exposure to endogenous hormones show relatively smaller burden of cerebral small vessel disease independent of history of oralcontraceptive use or hormone replacement therapy. Our results highlight the critical role endogenous hormones play in female brain health and provide real-world evidence of the protective effects premenopausalendogenous hormone exposure plays on postmenopausalcerebrovascular health.
- Open Access
- 4 September 2021
- Published by Wiley in Human Brain Mapping
- Vol. 42 (17) , 5677-5688
The regional effect of serum hormone levels on cerebral blood flow in healthy nonpregnant women
Sex hormones estrogen (EST) and progesterone (PROG) have received increased attention for their important physiological action outside of reproduction. While studies have shown that EST and PROG have significant impacts on brain function, their impact on the cerebrovascular system in humans remains largely unknown. To address this, we used a multi‐modal magnetic resonance imaging (MRI) approach to investigate the link between serum hormones in the follicular phase and luteal phase of the menstrual cycle (MC) with measures of cerebrovascular function (cerebral blood flow [CBF]) and structure (intracranial artery diameter). Fourteen naturally cycling women were recruited and assessed at two‐time points of their MC. CBF was derived from pseudo‐continuous arterial spin labeling while diameters of the internal carotid and basilar artery was assessed using time of flight magnetic resonance angiography, blood samples were performed after the MRI. Results show that PROG and EST had opposing and spatially distinct effects on CBF: PROG correlated negatively with CBF in anterior brain regions (r = −.86, p < .01), while EST correlations were positive, yet weak and most prominent in posterior areas (r = .78, p < .01). No significant correlations between either hormone or intracranial artery diameter were observed. These results show that EST and PROG have opposing and regionally distinct effects on CBF and that this relationship is likely not due to interactions with large intracranial arteries. Considering that CBF in healthy women appears tightly linked to their current hormonal state, future studies should consider assessing MC‐related hormone fluctuations in the design of functional MRI studies in this population.
- 4 September 2021
- Published by Wiley in Human Brain Mapping
- Vol. 42 (17) , 5677-5688
Open AccessThe regional effect of serum hormone levels on cerebral blood flow in healthy nonpregnant women
Sex hormones estrogen (EST) and progesterone (PROG) have received increased attention for their important physiological action outside of reproduction. While studies have shown that EST and PROG have significant impacts on brain function, their impact on the cerebrovascular system in humans remains largely unknown. To address this, we used a multi‐modal magnetic resonance imaging (MRI) approach to investigate the link between serum hormones in the follicular phase and luteal phase of the menstrual cycle (MC) with measures of cerebrovascular function (cerebral blood flow [CBF]) and structure (intracranial artery diameter). Fourteen naturally cycling women were recruited and assessed at two‐time points of their MC. CBF was derived from pseudo‐continuous arterial spin labeling while diameters of the internal carotid and basilar artery was assessed using time of flight magnetic resonance angiography, blood samples were performed after the MRI. Results show that PROG and EST had opposing and spatially distinct effects on CBF: PROG correlated negatively with CBF in anterior brain regions (r = −.86, p < .01), while EST correlations were positive, yet weak and most prominent in posterior areas (r = .78, p < .01). No significant correlations between either hormone or intracranial artery diameter were observed. These results show that EST and PROG have opposing and regionally distinct effects on CBF and that this relationship is likely not due to interactions with large intracranial arteries. Considering that CBF in healthy women appears tightly linked to their current hormonal state, future studies should consider assessing MC‐related hormone fluctuations in the design of functional MRI studies in this population.